PT - JOURNAL ARTICLE AU - Ben Ainsworth AU - Sabina Stanescu AU - Beth Stuart AU - Daniel Russell AU - Megan Liddiard AU - Ratko Djukanovic AU - Mike Thomas TI - A feasibility trial of a digital mindfulness-based intervention to improve asthma-related quality of life for primary care patients with asthma AID - 10.1101/2021.04.27.21256158 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.27.21256158 4099 - http://medrxiv.org/content/early/2021/04/29/2021.04.27.21256158.short 4100 - http://medrxiv.org/content/early/2021/04/29/2021.04.27.21256158.full AB - Objective Asthma outcomes remain suboptimal, despite effective pharmacotherapy. Psychological dysfunction (such as anxiety) is common, and associated with poorer outcomes. We evaluated a digital mindfulness programme as an intervention to improve asthma-related quality of life for primary care patients, in a prospectively registered randomized-controlled feasibility study.Methods We offered ‘Headspace’, a widely-used digital mindfulness intervention, to adults with asthma through 16 UK GP practices. Participants were randomised on a 2:1 basis to the mindfulness intervention, or waitlist control. Participants completed questionnaires (including asthma symptom control, asthma-related quality of life, anxiety, depression) at baseline, 6-week and 3-month follow-up.Results 114 participants completed primary outcomes at 3-month follow-up (intervention 73 (71.6%), control 41 (70.7%)). Compared to baseline, the intervention group but not the control group reported significantly improved asthma-related quality of life, with a non-significant between-group difference favouring the intervention group (Mean difference = 0.16, 95%CI: - 0.11 – 0.44). Intervention use varied but was generally high.Conclusions Digital mindfulness interventions are feasible and acceptable adjunct treatments for mild and moderate asthma to target quality of life. Further research should adapt ‘generic’ mindfulness-based stress-reduction to maximize effectiveness for asthma, and validate our findings in a fully-powered randomized controlled trial.Trial registration Prospectively registered: ISRCTN52212323Competing Interest StatementThe authors declare the following financial interests/personal relationships which may be considered as potential competing interests: BA has received fees for speaking at an educational meeting hosted by Astra Zeneca, and an expert advisory panel Roche. MT has received speaker's honoraria for speaking at sponsored meetings or satellite symposia at conferences from the following companies marketing respiratory and allergy products: GSK, Novartis. He has received honoraria for attending advisory panels with; Boehringer Inglehiem, GSK, Novartis,. He is a recent a member of the BTS SIGN Asthma guideline steering group and the NICE Asthma Diagnosis and Monitoring guideline development group. RD report personal fees from Synairgen, which is outside the submitted work. RD also reports receiving fees for lectures at symposia organized by Novartis, AstraZeneca and TEVA, consultation for TEVA and Novartis as member of advisory boards, and participation in a scientific discussion about asthma organized by GlaxoSmithKline. BS, DR, ML and SS have no conflicts of interest. Clinical TrialISRCTN52212323Funding StatementThe study was supported by a research project grant from the NIHR School of Primary Care (FR13:373). During this project BA was supported by an NIHR Post-doctoral Translational Fellowship from the NIHR School of Primary Care. The funding body had no input into design, analysis or interpretation of data, nor any input into the manuscript. The views expressed are those of the authors and not necessarily those of the NIHR, MRC, the NHS or the Department of Health. Headspace Inc. provided free access to their intervention for participants in the study. They had no input into design, analysis or interpretation of data, nor the decision to submit for publication, although were asked to provide information for the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was given by the South Central Hampshire Research Ethics Committee (17/SC/0088) and the University of Southampton Ethics and Research Governance Online (24515). The study was in line with The Code of Ethics of the World Medical Association (Declaration of Helsinki). All participants provided informed consent before taking part.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe analysis scripts used during the current study are available in the FIGSHARE repository. The data is available in line with the consent collected from participants; by request.ACQAsthma Control QuestionnaireAQLQAsthma Quality of Life QuestionnaireGPGeneral PractitionerHADSHospital Anxiety and Depression ScaleMARS-AMedical Adherence Report ScaleMBIsMindfulness-based InterventionsMBCTMindfulness-based Cognitive TherapyMBSRMindfulness-based Stress ReductionMCIDMinimum clinically important differenceMDMean DifferenceNIHRNational Institute of Health ResearchNNTNumber needed to treatOROdds ratioPHLMSPhiladelphia Mindfulness ScaleRCTRandomised Controlled Trial